Welcome to Solvotrin Therapeutics
Solvotrin Therapeutics Limited is a privately held pharmaceutical company with a portfolio of innovative products for the treatment of cardiovascular disease and cancer. Solvotrin Therapeutics’ intellectual property protects a family of bioactivated medicines with significant clinical advantages over currently available drugs.
Solvotrin Therapeutics is developing lead compound ST0702, a chemically modified niacin-aspirin prodrug, as a “no-flush” niacin for treating cholesterol problems. Niacin products form a billion dollar market, yet flushing is a major problem affecting most patients. ST0702 has preclinical proof-of-concept data on efficacy and safety in terms of lipid modification and reduced adverse events. ST0702 has also shown superior efficacy to aspirin as an antiplatelet drug for treatment of cancer and neoplastic diseases. An orphan indication has been identified for ST0702 in cholesterol and antiplatelet therapy areas.
Solvotrin Therapeutics’ strategy is to develop the lead compounds from its platform technology through to clinical testing. The Company’s targeted development approach seeks early confirmation of efficacy and tolerability advantages from in vitro and in vivo studies. Solvotrin Therapeutics intends to partner the later clinical development and commercialisation of the products with pharmaceutical companies that have established global sales and marketing operations, as well as strategic interests in its target indications.
Headquartered in Cork, Ireland, Solvotrin Therapeutics also has offices and laboratories in Dublin.
